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cultured with serum. Constitutive synthesis of tumor necrosisb2-Microglobulin modified with advanced glycation end prod-
factor-a (TNF-a), interleukin-1b (IL-1b) and prostaglandin E2ucts delays monocyte apoptosis.
(PGE2) increased in monocytes cultured for four to six daysBackground. A local inflammatory reaction to b2-microglob-
with AGE-b2m.ulin (b2m) amyloid deposits by monocytes/macrophages is a
Conclusions. These findings support a novel role for AGE-characteristic histologic feature of dialysis-related amyloidosis
modified proteins such as AGE-b2m that may contribute to(DRA). Since b2m modified with advanced glycation end prod-
the development of a local inflammatory response, with pre-ucts (AGE-b2m) is a major constituent of amyloid in DRA,
dominant accumulation of monocytes/macrophages, in DRA.we tested the hypothesis that AGE-b2m affects apoptosis and
phenotype of human monocytes.
Methods. Human peripheral blood monocytes were incu-
bated with or without in vitro-derived AGE-b2m, and their Dialysis-related amyloidosis (DRA) is a progressiveviability, extent of apoptosis, morphology, and function exam-
and incapacitating condition that affects patients withined over the subsequent four days.
Results. AGE-modified but not unmodified b2m significantly chronic renal failure [1, 2]. Amyloid fibrils that contain
delayed spontaneous apoptosis of human peripheral blood the subunit protein b2-microglobulin (b2m) deposit pre-
monocytes in adherent and nonadherent cultures. The effect dominantly in osteoarticular tissue, causing shoulder per-of AGE-b2m on monocytes apoptosis was time- and dose- iarthritis, carpal tunnel syndrome, hand flexor tenosyno-dependent and was attenuated by a blocking antibody directed
vitis, destructive spondyloarthropathy, and cystic boneagainst the human AGE receptor (RAGE). There was no
difference in effect between AGE-b2m and that of AGE-modi- lesions [1, 2]. Histologic examination of osteoarticular
fied human serum albumin. Culture of monocytes with AGE- tissue from patients with DRA reveals a local inflamma-
b2m did not alter membrane expression of Fas or Fas ligand. tory reaction to deposited amyloid by monocytes/macro-Monocytes cultured with AGE-b2m underwent substantial phages [3–5]. The predominant location of these infiltrat-changes in morphology similar to those observed when mono-
ing cells around blood vessels or adjacent to the amyloidcytes differentiate into macrophages. The cultured cells in-
creased in size and vacuolization, and their content of b-glucu- deposits suggests that the infiltrating monocytes are re-
ronidase and acid phosphatase increased by 5- to 10-fold at cruited from the peripheral blood. The observation that
day 4. Expression of the monocyte–macrophage membrane they produce interleukin-1b (IL-1b) and tumor necrosisantigens HLA-DR, CD11b, and CD11c also increased at day 4.
factor-a (TNF-a) suggests that they are primed [6, 7].Although exhibiting phenotypic characteristics of macrophages,
A subtle balance between recruitment and constitutivemonocytes cultured with AGE-b2m functioned differently than
macrophages cultured with serum. Superoxide production in death of inflammatory cells regulates inflammatory re-
response to phorbol myristic acetate was maintained in mono- sponses within the microenvironment [8]. Monocytes
cytes cultured with AGE-b2m, but declined with time in cells and macrophages play significant roles in the exacerba-
tion and resolution of acute and chronic inflammation.
Thus, regulation of monocyte/macrophage survival andKey words: amyloidosis, cell death, dialysis, inflammation, chronic re-
nal failure. maturation might be critical in controlling their presence,
and hence their biologic affect, in inflammatory lesionsReceived for publication February 23, 2000
[9]. Human peripheral blood monocytes undergo pro-and in revised form October 2, 2000
Accepted for publication October 6, 2000 grammed cell death, or apoptosis, when cultured in the
absence of appropriate stimuli. Certain inflammatory cy-Ó 2001 by the International Society of Nephrology
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tokines, such as IL-1b and TNF-a, but not chemotactic Synthesized pentosidine or CML were prepared in
vitro according to our previous method [19] Bovine se-factors, prevent monocyte apoptosis and thus maintain
cell viability in vitro [10]. Because monocyte differentia- rum albumin (BSA) modified with pentosidine (pentosi-
dine-BSA) or CML (CML-BSA) was prepared by conju-tion into macrophages occurs over a period of several
days [11], monocyte survival is a fundamental component gating synthesized pentosidine or CML with BSA [19].
All samples contained ,0.05 U/mL (5 pg/mL) of endo-of their maturation.
b2m modified with advanced glycation end products toxin as measured by a limulus amebocyte lysate assay
(Sigma) at 32 the working dilution used for the experi-(AGE) is a major component of amyloid deposits in
DRA [12]. Human monocytes/macrophages express spe- ments.
cific receptors for AGE [13]. Interaction of AGE-modi-
Isolation and culture of human monocytesfied b2m (AGE-b2m) with the receptor for AGE (RAGE)
on monocytes/macrophages increases monocyte migra- Human mononuclear leukocytes, from the whole blood
of healthy volunteers not ingesting steroidal or nonste-tion and priming [14, 15]. The display of these proin-
flammatory functions by infiltrating mononuclear phago- roidal anti-inflammatory drugs, were separated from other
cell types by sedimentation in 6% dextran and centrifu-cytes depends on their continued survival within the tis-
sue microenvironment. Therefore, we examined the ef- gation through Ficoll-Paque [20]. Monocytes were iso-
lated and purified by CD14 positive immunomagneticfect of AGE-b2m on monocyte survival and maturation
in vitro. The demonstration of an effect of AGE-b2m on selection using VS1 columns and Vario MACS system
according to the manufacturer’s technical guidelines (Mi-monocyte apoptosis would offer a novel regulatory step
in the pathobiology of this debilitating complication of lienvi Bioiec, Auburn, CA, USA). Final monocyte puri-
fication was reproducibly .99% as demonstrated byrenal failure.
Wright’s stain morphology and phenotypic characteriza-
tion (CD11c1, CD252) analyzed by a FACScan flow cy-
METHODS
tometer (Becton Dickinson, Mountain View, CA, USA).
In vitro preparation of AGE-modified proteins, CML, Monocytes were cultured in RPMI 1640 (GIBCO
and pentosidine BRL, Gaithersburg, MD, USA) with 20 mmol/L l-gluta-
mine, 25 mmol/L HEPES buffer (GIBCO BRL), 10AGE-modified proteins were prepared in vitro as pre-
viously described with slight modification [16]. Briefly, mmol/L 2-mercaptoethanol (GIBCO BRL), penicillin,
and streptomycin, either containing various amounts of2.5 mg/mL of purified normal human b2m (BiosPacific,
Emeryville, CA, USA) or human serum albumin (HAS; AGE-b2m, unmodified b2m, 10% autologous serum, or
no additives. The monocytes were cultured in 17 3 100Sigma, St. Louis, MO, USA) was incubated at 378C for
eight weeks with 200 mmol/L d-glucose in 100 mmol/L mm polypropylene tubes (nonadherent cultures of 2 3
106/0.5 mL tubes) or in 24-well polystyrene plates (adher-phosphate buffer containing penicillin and gentamicin.
Samples incubated in an identical manner in the absence ent cultures of 2 3 106/1.0 mL wells) at 378C in 5% CO2
and high humidity. All media and reagents containedof glucose were used as controls. After incubation, all
samples were dialyzed against phosphate buffer (pH 7.4). ,0.05 U/mL endotoxin.
AGE modification was characterized by ELISA using
Analysis of monocytes/macrophages viabilityan anti-AGE antibody (gift of Dr. John W. Baynes, Uni-
versity of South Carolina, Columbia, SC, USA) [12, 16]. At different times after culture initiation, the cell in
nonadherent cultures were centrifuged and resuspendedThis antibody specifically reacts with AGE but not with
the early products of the Maillard reaction [17]. AGE- in phosphate buffer (pH 7.4). The adherent cultured cells
were detached from the plates by vigorous pipetting aftermodified proteins were also characterized and quanti-
tated by fluorospectrometry as previously described incubation with versene 1/5000 (GIBCO BRL) for 5 to
10 minutes. The harvested cells were centrifuged with[12, 16]. The AGE content of the products was 42.1 U/mg
protein for AGE-b2m, 43.0 U/mg protein for AGE-HSA their supernatants that contained floating cells and resus-
pended in phosphate buffer. One volume of trypan blueand 0.8 U/mg protein for b2m control. The pentosidine
content, as measured by high-performance liquid chroma- (0.4%) was added to five volumes of cells suspension.
After five minutes of incubation, the cells were countedtography (HPLC) [18], was 135 pmol/mg for AGE-b2m
and 1.4 pmol/mg for b2m control. The carboxymethyllys- in duplicate and considered viable if able to exclude
trypan blue.ine (CML) content, as determined by mass spectrometry
[18], was 43.8 nmol/mg for AGE-b2m and less than 0.1
Assessment of apoptosisnmol/mg for b2m control (lower limit of detection of the
assay). These results confirm the presence of chemically Apoptosis was assessed by the following three methods.
Measurement of cellular DNA contents. The percent-identified AGE in AGE-modified b2m, but not in the
control sample. age of apoptotic cells was quantitated by DNA content
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analysis after extraction of the degraded DNA from the for four days with RPMI 1640 with 10% autologous
serum or with serum-free medium containing 100 mg/mLcells [21]. Briefly, freshly isolated or cultured cells were
fixed in 70% (vol/vol) ice-cold ethanol and stored at of AGE-b2m. Morphologic changes of the cells were ob-
served though an inverted microscopy (Nikon TMS). At2208C for one to two days. The fixed cells were pelleted,
resuspended in 0.5 mL of phosphate buffer, and incu- the end point of culture, the cells were detached from the
plates as described above and fixed in 1.25% glutaralde-bated at room temperature for five minutes with 1.0
mL of DNA extraction buffer. The cells were spun and hyde in cacodylate buffer containing 1% CaCl2. Fixed cells
were washed in Sabatini’s solution and postfixed in 1%suspended in 250 mL of phosphate buffer containing
20 mg/mL of propidium iodide (Sigma) and 25 mg/mL osmium tetroxide. After washing, cells were dehydrated
in ethanol followed by treatment with propylene oxide.DNase-free RNase (Boehringer Mannheim, Indianapo-
lis, IN, USA). Cells were held for 30 minutes in the dark Ultrathin sections were stained with uranyl acetate and
lead citrate and examined by a transmission electron mi-at room temperature and then stored at 48C for eight
hours. DNA content was analyzed using a FACScan flow croscopy (JEOL 100CX; JEOL, Tokyo, Japan).
cytometry (FACs).
Immunophenotype analysisFluorescent TUNEL and Hoechst 33258 staining. DNA
strand breaks in individual cells were identified using Fresh isolated monocytes or cells cultured for four days
in RPMI 1640 with 10% autologous serum or serum-an in situ nick/end-labeling technique (TUNEL) [22].
Morphological changes in cells undergoing apoptosis free medium containing 100 mg/mL of AGE-b2m were
detached from the plates. The cells were washed, re-were detected simultaneously by counterstaining cells
with Hoechst 33258. Briefly, cytospins of harvested cells suspended in PBS with 0.5% human serum albumin, and
incubated for 60 minutes in ice with 1:50 diluted mono-were fixed for 10 minutes in 2% paraformaldehydrate
followed by methanol. After washing with TdT buffer clonal antibody (mAb) against HLA-DR (PharMingen,
San Diego, CA, USA), CD11b (Mac-1; PharMingen),(GIBCO BRL), cells were incubated in TdT buffer con-
taining 20 U/mL TdT (GIBCO BRL) and 20 nmol/L CD11c (P150; PharMingen), or isotype-matched irrele-
vant controls [24]. Primary mAb were detected usingbiotinylated dUTP (Boehringer Mannheim) at 378C for
60 minutes. The enzymatic reaction was terminated by 1:50 diluted FITC-conjugated rat antimouse Ig, k light
chain (PharMingen). Mean fluorescence intensity (MFI)placing the slides in terminal buffer (30 mmol/L sodium
citrate, 300 mmol/L sodium chloride). The slides were and forward light scatter (FSC; correlated with cell size)
were analyzed with FAScan [25, 26]. The results arethen blocked in phosphate buffer supplemented with 2%
bovine serum albumin (BSA) and followed by incuba- presented as overlaid histograms and the magnitude in-
crease of MFI (MFI units of tested mAb staining/MFItion with streptavidin-FITC (Fisher, Pittsburgh, PA,
USA) and 0.5 mg/mL of Hoechst 33258 (Sigma) for 60 units of matched isotype control mAb staining).
For determination of Fas and Fas ligand (FasL) ex-minutes. Slides were examined by fluorescent micros-
copy (Nikon FXA). pression, 1 3 106 monocytes were seeded in 24-well plates
and cultured with RPMI 1640–10% autologous serumDNA electrophoresis. DNA extraction and electro-
phoresis were performed as described previously [23]. or with serum-free medium in the presence or absence
of 50 to 200 mg/mL of AGE-b2m for 10 to 48 hours. TheIn brief, cells were collected and lysed by a DNA lysing
buffer [20 mmol/L Tris, pH 7.4, 5 mmol/L ethylenedi- cells were then incubated with 1:50 diluted mouse anti-
human Fas (PharMingen), mouse anti-human FasLaminetetraacetic acid (EDTA), and 0.4% Triton X-100].
After centrifugation at 14,000 r.p.m. for 10 minutes, su- (PharMingen), or an equal amount of mouse IgG1 (iso-
type control) for 60 minutes in ice. Immunoreactivitypernatants were extracted with a 25 phenol:24 chloro-
form:1 isoamyl alcohol mixture (GIBCO BRL). Next, was detected by 1:50 diluted FITC-conjugated rat anti-
mouse Ig, k chain.100 mL 5 mol/L NaCl and 500 mL isopropanol were
added to each tube before incubating overnight at
Quantitation of intracellular lysosomal enzymes2708C. Samples were centrifuged, washed once with
70% ethanol, and dried in a Speed-Vac. The lyophilized Acid phosphatase and b-glucuronidase were assayed
as previously described [22, 24]. In briefly, fresh isolatedpellet were resuspended in 30 mL of Tris-EDTA buffer
containing 0.1 mg/mL RNase A (Sigma) and incubated monocytes were adhered to plates for two hours or incu-
bated for four days in RPMI 1640 with 10% autologousat 378C for 30 minutes. Equal amounts of DNA were
separated on 0.8% agarose gels and visualized by ethid- serum or serum-free medium containing AGE-b2m (100
mg/mL). The cells were then harvested as described pre-ium bromide staining under ultraviolet light.
viously in this article, counted, and lyzed with 0.1% Tri-
Morphology and ultrastructure examination ton X-100. The microassay was performed in 96-well
microtiter plates using p-nitrophenolphosphate (for acidFreshly isolated monocytes were adhered to 24-well
polystyrene plates for two days (day 0) or incubated phosphatase assay; Sigma) or p-nitrophenyl-b-D-glu-
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curonide (for b-glucuronidase assay; Sigma) as enzyme RESULTS
substrates. The plates were incubated at 378C for one Effect of AGE-b2m on monocyte apoptosis
hour, and the absorbency was determined at 405 nm in Immediately after isolation, only 2 to 3% of the mono-
an ELISA reader (Titertek Multiskan Mcc/340). One cytes were nonviable, as determined by permeability to
unit of enzyme activity represented cleavage of 1 mmol trypan blue (Fig. 1A, C, and apoptotic cells were less than
of substrate per hour. 1% as analyzed by flow cytometry (Fig. 1B, D). The per-
centage of trypan blue-positive monocytes and apoptoticAssay for superoxide production
cells increased over time when the cells were cultured
Superoxide release in response to stimulation with 10 in suspension in RPMI 1640 alone. Incubation of nonad-
mg/mL of phorbol myristate acetate (PMA; Sigma) was herent monocytes with 10% autologous serum had no
determined as has been described by Pick and Mizel effect on viability and apoptosis. In contrast, incubation
[27]. Monocytes were cultured in 96-well plates with of nonadherent monocytes with AGE-b2m maintained
RPMI 1640 with 10% autologous serum or serum-free monocyte viability (Fig. 1A) and significantly decreased
medium containing 100 mg/mL AGE-b2m for two hours apoptosis (Fig. 1B). A similar number of monocytes were
to six days. The culture medium was removed and re- recovered from cultures with or without AGE-b2m (dif-
placed with Hanks’ buffer containing 160 mmol/L of ferri- ference ,16%), indicating that the cells were not under-
cytochrome C (Sigma), with and without PMA, and with going autolysis.
and without 300 U/mL superoxide dismutase (Sigma). Since adherence impacts selected monocyte functions
The plates were incubated at 378C for one hour and the [28], such as cytokine elaboration, we examined the ef-
fect of AGE-b2m on adherent monocytes. When incu-absorbency was determined at 540 nmol/L. The results
bated in serum-free medium, cells adhering to tissueare expressed as nanomoles O22 per 106 cells per hour.
culture plates underwent cell death and apoptosis at ap-
Quantitation of TNF-a, IL-1b, and PGE2 production proximately the same rate as nonadherent monocytes
(Fig. 1C, D). However, when autologous serum (10%)Monocytes (1 3 106) were cultured in duplicate in
was added to the cultures, more than 90% of cells sur-RPMI 1640 with 10% autologous serum or with serum-
vived for 72 hours without undergoing apoptosis (P ,free medium containing 100 mg/mL of AGE-b2m from
0.0001). AGE-b2m also attenuated cell death and apo-two hours to six days. The monolayers were washed two
ptosis in adherent monocytes (P , 0.0001). After 72 hourstimes with PBS and then fresh medium with or without
of culture in the presence of AGE-b2m (100 mg/mL),1 mg/mL of lipopolysaccharide (LPS; from Escherichia
about 60% of monocytes were viable and had not under-coli 026:B6; Sigma) or 100 mg/mL of AGE-b2m was
gone apoptosis.added. The culture was performed in 24-well plates.
To determine the dose-related effect of AGE-b2m onAfter 18 hours (for LPS stimulation) or 24 hours (for
monocyte viability, monocytes were cultured in suspen-AGE-b2m stimulation), supernatants were harvested
sion in serum-free medium containing various concen-and centrifuged at 400 3 g for five minutes. The cells
trations of AGE-b2m (Fig. 2). As assessed by FACs,were detached and counted as described above. TNF-a
AGE-b2m treatment delayed apoptosis in a dose-depen-and IL-1b levels were measured in duplicate in each
dent manner (P , 0.0001). Experiments performed using
supernatant with ELISA kits according to the manufac-
adherent monocytes yielded similar results. AGE-b2m atturer’s technical guidelines (TNF-a, Genzyme, Cam- concentrations of 50 mg/mL, 100 mg/mL, and 200 mg/mL
bridge, MA, USA; IL-1b, Endogen, Woburn, MA, decreased the proportion of apoptotic cells to 79, 47,
USA). PGE2 was quantitated by radioimmunoassay us- and 42%, respectively, of that observed with medium
ing rabbit anti-PGE2 (Sigma) according to the manufac- alone (data not shown).
turer’s protocol. Monocytes cultured in serum-free medium developed
morphologic characteristics of apoptosis, including pyk-
Statistical analysis
notic nuclei, chromatin condensation, and nuclear fragmen-
All experiments were performed in triplicate. Contin- tation, as identified by Hoechst 33258 staining (Fig. 3C).
uous variables, expressed as mean 6 SD, were compared DNA strand breaks in these cells were demonstrated by
using analysis of variance (ANOVA). Multiplicative in- TUNEL (Fig. 3D). Culture of monocytes with 100 mg/mL
teraction terms were included to evaluate for interaction AGE-b2m attenuated the development of morphologic
terms among explanatory variables. The Student-New- features of apoptosis (Fig. 3G) and of DNA breaks (Fig.
man-Keuls procedure was used to evaluate pairwise com- 3H), whereas unmodified b2m had no effect on either
parisons. Two-tailed P values ,0.05 were considered morphologic signs of monocyte apoptosis (Fig. 3E) or
statistically significant. Statistical analyzes were con- DNA breaks (Fig. 3F). AGE-b2m, but not unmodified
b2m, also diminished DNA internucleosomal fragmenta-ducted with SAS (The SAS Institute, Cary, NC, USA).
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Fig. 1. Kinetics of cell death and apoptosis in monocytes. Monocytes were cultured in polypropylene tubes (A and B) or in 24-well polystyrene
plates (C and D) in RPMI 1640 with no added stimulant (d), 10% autologous serum (s), b2m (m), or 100 mg/mL of AGE-b2m (n). The percentages
of nonviable (trypan blue positive cells; A and C) and apoptotic cells (B and D) were determined. Apoptosis was quantitated by flow cytometry.
Monocytes from the same donor preparation were used in each experiment to assure compatible conditions Data are the mean of triplicate
experiments that did not vary by more than 15% (ANOVA, P , 0.0001; duration of incubation, P , 0.0001; culture condition, P , 0.0001; duration
of incubation 3 culture condition, P , 0.0001).
tion, as identified by electrophoresis on DNA gels (data of AGE-b2m, had no effect on monocyte apoptosis. The
lack of a difference between the effect of AGE-b2m andnot shown).
that of AGE-HSA (Fig. 4), indicates that the observed
Blocking of RAGE attenuates the effect of AGE-b2m effect on the inhibition of apoptosis was due to AGE-
modification of the protein and was not a property spe-To ascertain the specificity of the effect of AGE-b2m
on monocyte apoptosis, adherent monocytes were pre- cific to b2m.
incubated with 50 mg/mL of rabbit anti-human RAGE
Chemical nature of the AGEor nonimmune rabbit IgG for two hours. This concentra-
tion of anti-human RAGE has previously been demon- To clarify the chemical nature of the AGE responsible
for the effect on monocyte apoptosis, adherent mono-strated to block other effects of AGE-b2m in vitro [29].
The monocytes were then cultured with 100 mg/mL of cytes were cultured with serum-free medium, AGE-b2m
(100 mg/mL) pentosidine-BSA (100 mg/mL), CML-BSAAGE-b2m for 30 hours. The antibody that blocks the
interaction of AGE-b2m and RAGE in other systems (100 mg/mL), synthesized pentosidine (10 or 1000 pmol)
and synthesized CML (2 or 200 nmol) for 30 hours.[14, 16, 29] significantly diminished the capacity of AGE-
b2m to prevent monocyte apoptosis (P , 0.0001; Fig. 4). Percent trypan blue positive cells and apoptotic cells
were quantitated as described previously in this articleThese findings are not a consequence of LPS contamina-
tion, since polymyxin B (10 mg/mL) did not change the (Table 1). AGE-b2m containing cultures had less apo-
ptotic (24.3 6 3.5%) and trypan blue positive cellseffect of AGE-b2m on monocyte survival (data not
shown). In addition, unmodified b2m, which was pre- (31.5 6 3.1%) compared with cultures containing me-
dium alone (controls, 52.0 6 4.0% and 56.3 6 4.5%,pared using the same conditions as in the preparation
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were cultured with AGE-b2m for longer than four days,
their survival was extended even after AGE-b2m was
removed from the culture. By day 4 of culture with
AGE-b2m, the cells no longer required the presence
of AGE-b2m to survive. Parallel experiments with cul-
tures using 10% autologous serum yielded similar results.
Monocytes cultured with serum for four days no longer
required serum for survival after that time (results
not shown).
Effect of AGE-b2m on Fas and FasL expression
on monocytes
Because it has been suggested that Fas–FasL interac-
tion is involved in the induction of spontaneous apoptosis
of monocytes [30], we tested the effect of AGE-b2m on
monocyte expression of Fas and FasL. Monocytes were
incubated in polypropylene tubes in serum-free medium
or in medium with 10% autologous serum, with or with-
Fig. 2. Dose-dependent effect of AGE-b2m on apoptosis in monocytes. out AGE-b2m for 10 to 48 hours. FACs analysis showedMonocytes were cultured for 30 hours in serum-free RPMI 1640 in poly-
that AGE-b2m did not affect the expression of Fas orpropylene tubes containing the indicated concentration of AGE-b2m.
Percent trypan blue positive cells (n) and apoptotic cells (d) were then FasL on monocytes, cultured either in serum-free me-
determined as described in the text. Data are expressed as mean 6 SD dium or in medium with 10% autologous serum, at any
of triplicate cultures from one donor and are representative of data
time tested (data not shown).from three donors (ANOVA, P , 0.0001). Data values from cultures
stimulated with $50 mg/mL AGE-b2m are significantly different from
Morphology and ultrastructure of monocytes culturedcontrols without AGE-b2m.
with AGE-b2m
Monocytes cultured with serum for longer than three
days differentiate into macrophage-like cells [24, 26].N 5 3, P , 0.01). In contrast, monocytes cultured with
Eighty percent of monocytes cultured with serum-free
pentosidine-BSA or CML-BSA underwent apoptosis
medium or medium containing unmodified b2m were apo-(49.1 6 7.5% and 50.6 6 9.1%, respectively) and cell ptotic within 48 hours (Fig. 1) and incapable of differentia-
death (54.3 6 8.1% and 53.0 6 12.1%, respectively) at tion in vitro. Since 60% of adherent monocytes cultured
rates no different from controls (P . 0.05). Similarly, with AGE-b2m were viable at day 3 of the cultures, weneither free pentosidine nor free CML could protect examined the morphologic and functional characteristics
monocytes from apoptosis or cell death. Apoptotic cells of these cells. Using inverted microscopy, monocytes cul-
were 50.0 6 8.7% and 50.6 6 9.5% when cultured in tured with AGE-b2m (Fig. 6C) or with 10% autologousthe presence of 10 pmol and 1000 pmol of pentosidine, serum (Fig. 6B) for four days appeared to be larger than
respectively; 49.6 6 8.0% and 51.3 6 8.3% in 2 nmol freshly isolated monocytes (Fig. 6A) and were predomi-
and 200 nmol of CML, respectively (N 5 3, P . 0.05 nantly circular with increased numbers of lipid inclusions.
compared with controls). Trypan blue positive cells were However, monocytes cultured with AGE-b2m (Fig. 6C)
55.0 6 7.8 and 53.3 6 10.5% in 10 pmol and 1000 pmol were smaller than monocytes cultured with 10% autolo-
of pentosidine, respectively; 52.3 6 9.0% and 55.6 6 gous serum (Fig. 6B) and had more pseudopodia. Elec-
7.9% in 2 nmol and 200 nmol of CML, respectively (N 5 tron microscopic examination demonstrated that after
3, P . 0.05 compared with controls). incubation for four days, the ultrastructural changes of
monocytes cultured with AGE-b2m were similar to thoseDuration of AGE-b2m effect on apoptosis of cells cultured with 10% autologous serum. Monocytes
To determine whether inhibition of monocyte apoptosis cultured with either AGE-b2m or 10% autologous serum
persists after removal of AGE-b2m, monocytes were cul- displayed morphology typical of mature macrophages
tured in 24-well polystyrene plates with AGE-b2m (100 with increased and thickened cytoplasmic processes, in-
mg/mL) for two hours to six days. The cells were washed, creased phagocytic vacuoles, crystal inclusions, and sec-
detached from the wells, resuspended in fresh serum- ondary lysosomes in the cytoplasm (Fig.6 E, F).
free medium without AGE-b2m, and further cultured in
Effect of culture with AGE-b2m on macrophagethe polystyrene plates at 1 3 105 cells/1.0 mL/well for an
membrane antigen developmentadditional 48 hours. Removing AGE-b2m from the cul-
ture at or before 48 hours resulted in a rapid decrease in Monocytes cultured for four days with AGE-b2m were
analyzed for expression of the macrophage surface anti-monocyte viability (Fig. 5). However, when monocytes
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Fig. 4. Effect of AGE-b2m, AGE-HAS, and
anti-RAGE on monocyte apoptosis. Mono-
cytes were cultured in RPMI 1640 alone (con-
trol), 100 mg/mL AGE-b2m, or 100 mg/mL
AGE-HSA for 30 hours. In indicated wells,
cells were preincubated with 50 mg/mL rabbit
anti-human RAGE IgG or nonimmune rabbit
IgG for 2 hours and then cultured with 100
mg/ml AGE-b2m for 30 hours. Percent trypan
blue positive cells (h) and apoptotic cells (j)
were determined. Data are mean 6 SD of
triplicate experiments and are presented as
percentage trypan blue positive cells and apo-
ptotic cells in control cultures (ANOVA, P ,
0.0001). The RAGE-treated group is signifi-
cantly different from rabbit IgG treated and
AGE-b2m alone group.
gens, HLA-DR, CD11b, and CD11c. Monocytes cul- Superoxide production in monocytes cultured
with AGE-b2mtured with AGE-b2m or with 10% autologous serum
exhibited a shift in the mean fluorescence intensity when Superoxide production in serum-containing cultures de-
stained for these membrane epitopes. However, the rela- clines as monocytes change phenotype into macrophages
tive increase in mean fluorescence intensity was less for [30]. After stimulation with PMA, monocytes freshly
monocytes cultured with AGE-b2m than for those cul- isolated or cultured for four or six days with 10% autolo-
tured with 10% autologous serum (Table 2). gous serum elaborated 52.4 6 4.1, 25.8 6 2.7, and 11.7 6
1.9 nmol/L of superoxide per 60 minutes per 106 cells,
Enhancement of intracellular lysosomal enzyme respectively (N 5 3). In contrast, monocytes cultured
content of monocytes cultured with AGE-b2m with 100 mg/mL of AGE-b2m generated significantly
Increased levels of lysosomal enzymes accompany phe- more superoxide after PMA stimulation at four and six
notypic transformation of monocytes into macrophages days. The cells produced 52.9 6 3.3, 49.8 6 3.8, and
[24, 31]. To evaluate the effect of AGE-b2m on this com- 44.3 6 4.2 nmol/L of superoxide per 60 minutes per
ponent of transformation, acid phosphatase and b-glucu- 106 cells at the same time points, respectively (N 5 3,
ronidase activity were assessed in monocytes cultured with ANOVA, P , 0.0001; duration of incubation, P ,
AGE-b2m or with 10% autologous serum for four days. 0.0001; culture condition, P , 0.0001; duration of incu-
Freshly isolated monocytes contained 180.0 6 3.0 units bation 3 culture condition interaction, P , 0.0001).
of acid phosphatase per 106 viable cells. After four days of
Production of TNF-a, IL-1b, and PGE2 in monocytesculture with 100 mg/mL of AGE-b2m or 10% autologous
developed with AGE-b2mserum, acid phosphatase activity increased to 2130.0 6
130.0 and 3120.0 6 90.0 U/106 viable cells, respectively A critical function of macrophages is the synthesis
(N 5 3, P , 0.0001). Freshly isolated monocytes contained and secretion of proinflammatory cytokines and lipid
7.0 6 0.3 units of b-glucuronidase per 106 viable cells, inflammatory mediators in response to biologic stimuli.
which increased to 35.0 6 10.0 and 50.4 6 0.7 U/106 viable Therefore, we quantitated the production of TNF-a,
cells by four days of culture with AGE-b2m and 10% IL-1b, and PGE2 in response to LPS or AGE-b2m. Pre-
liminary experiments demonstrated that LPS-inducedautologous serum, respectively (P , 0.0001).
b
Fig. 3. Detection of morphological signs of apoptosis and DNA strand breaks in monocytes cultured in polypropylene tubes. Fresh isolated mono-
cytes (A and B), monocytes cultured for 30 hours in serum-free medium (C and D), in 100 mg/mL of unmodified b2m (E and F ), and in 100 mg/mL
of AGE-b2m (G and H ) were counterstained with Hoechst 33258 and fluorescent TUNEL. The photographs were taken using an fluorescence
microscopy (3100). The arrows indicate apoptotic monocytes. Reproduction of these illustrations in color was made possible by the support of
Amgen, Inc., Thousand Oaks, CA, USA.
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Table 1. Effect of various advanced glycation end products (AGE)
on monocyte apoptosis
AGE Trypan blue positive Apoptotic cells
Serum-free medium 56.364.5 52.064.0
AGE-b2m 100 lg/m 31.563.1 24.363.5
Pentosidine-BSA 100 lg/mL 54.368.1 49.167.5
CML-BSA 100 lg/mL 53.0612.1 50.669.1
Pentosidine
10 pmol 55.067.8 50.068.7
1000 pmol 53.3610.5 50.669.5
CML
2 nmol 52.369.0 49.668.0
200 nmol 55.667.9 51.368.3
Adherent monocytes were cultured for 30 hours with serum-free medium
without or containing 100 mg/mL of AGE-b2m, pentosidine-BSA (100 mg/mL),
CML-BSA (100 mg/mL), synthesized pentosidine (10 or 1,000 pmol), and synthe-
sized CML (2 or 200 nmol). The percentages of nonviable (trypan blue positive
cells) and apoptotic cells were determined. Apoptosis was quantitated by flow
cytometry. The data are expressed as mean 6 SD of 3 cultures.
Fig. 5. Effect of duration of AGE-b2m exposure on the survival of
monocytes. Monocytes were cultured in polystyrene plates withsecretion of TNF-a, IL-1b and PGE2 was maximal at 18 AGE-b2m (100 mg/mL) for the number of days indicated. The cellshours, whereas AGE-b2m–induced secretion was maxi- were washed, detached from the wells, respuspended in fresh serum-
free medium, and further cultured in polystyrene plates at 1 3 105 cells/mal at 24 hours (data not shown). Thus, monocytes were
1.0 mL/well. Survival (d) and apoptotic cells (n) were quantitated aftercultured with AGE-b2m or 10% autologous serum for culture for an additional 48 hours. The results are expressed as mean
two hours or for four or six days, washed, and stimulated of triplicate experiments that did not vary by more than 10%.
with LPS for 18 hours or with AGE-b2m for 24 hours.
After two hours (day 0), there was no difference in cyto-
kine levels between AGE-b2m- and serum-containing
tic histologic feature of DRA [3, 5]. Because AGE-modi-cultures (Table 3). After four days of culture, the consti-
fied b2m is chemotactic for human monocytes [15], andtutive production of TNF-a and IL-1b decreased in cells
monocytes/macrophages have receptors for the endo-cultured with serum, but increased in cells cultured with
cytic uptake of AGE-modified proteins [33], AGE-b2m–AGE-b2m. Monocytes cultured with AGE-b2m for four
forming amyloid has been proposed to account for theand six days spontaneously secreted more TNF-a and
preferential localization of monocytes/macrophages toIL-1b than did cells after two hours of culture (day 0)
these deposits [15]. However, the accumulation of short-or cells cultured with serum for the same duration of
lived cells at an inflammatory focus suggests a changetime (P , 0.0001). The effect of culturing monocytes
in their rate of programmed cell death [8–10].with AGE-b2m or 10% autologous serum on PGE2 pro-
The results reported herein characterize a novel biologi-duction was similar to those observed on cytokine secre-
cal property of AGE-modified proteins, like AGE-b2m.tion. Higher levels of PGE2, both in the absence and in
AGE-b2m delays spontaneous apoptosis, or programmedthe presence of LPS, were detected in cells cultured for
cell death, of human monocytes in vitro. In that humanfour to six days with AGE-b2m as compared with those
monocytes undergo apoptosis when placed in culture,cultured with 10% autologous serum (P , 0.0001).
AGE-b2m inhibited monocyte apoptosis in a dose- andTo determine how long increased cytokine secretion
time-dependent manner. AGE-modified proteins suchpersists after withdrawal of AGE-b2m, cells cultured with
as AGE-b2m are unique in this report in that other che-AGE-b2m for four days were washed and subsequently
motactic factors for monocytes, such as TGF-b, MCP-1,incubated with fresh medium alone. Every 24 hours, the
and C5a, do not maintain monocyte survival [10].supernatants and the cells from two wells were harvested,
It was previously assumed that the recruitment ofand fresh medium was replaced in the remaining wells.
monocytes to an inflammatory site was insufficient toIncreased TNF-a and IL-1b production persisted for
prevent monocyte apoptosis. Arguably, an additionalthree days after removal of AGE-b2m and subsequently
regulatory signal(s) was needed within the microenviron-returned to baseline levels after an additional four days
ment [10]. Unlike most conventional monocyte chemo-(data not shown).
tactic factors, AGE-b2m is able to provide signals for
both recruitment and survival. Monocyte apoptosis is
DISCUSSION critical because it is a provocateur for cell removal and
it results in the loss of functionally responsive cells [34].A local inflammatory reaction to b2m amyloid deposits
that involve monocytes and macrophages is a characteris- Regulation of apoptosis may be a highly efficient mecha-
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Fig. 6. Morphologic and ultrastructural characteristics of fresh isolated monocytes (A and D), monocytes cultured for four days with RPMI
1640–10% autologous serum (B and E ), and with serum-free medium containing 100 mg/mL AGE-b2m (C and F). All cell preparations, which were from
the same donor, were photographed with a 320 phase-contrast objective on a Nikon inverted microscopy (A–C) and then harvested and examined
by transmission electron microscopy (D–F). Monocytes cultured with either AGE-b2m or 10% autologous serum displayed morphology typical
of mature macrophages. However, monocytes matured in AGE-b2m (F) were smaller than those cultured with serum (E) and had fewer vacuoles.
nism for controlling the number of viable monocytes in cantly diminished by an antibody that blocks the interac-
tion of AGE protein and RAGE both in vitro and inan inflammatory lesion. Therefore, the delay of apoptosis
by local AGE-b2m may contribute to the accumulation vivo [14, 33], indicating that the protective effect of
AGE-b2m on monocyte apoptosis is AGE receptor me-of monocytes/macrophages observed in DRA.
AGE-b2m, but not unmodified b2m, delayed apoptosis diated. RAGE is a 35 kD member of the immunoglobulin
superfamily of receptors, which is present on variousof monocytes. Furthermore, this effect was no different
from that of AGE-HSA, suggesting that the inhibition types of cells including human mononuclear phagocytes
[14, 34, 35]. Human AGE-b2m binds to the extracellularof apoptosis was due to AGE modification of the protein
and not a specific property of AGE-b2m. The capacity domain of RAGE with a kD <83.5 nmol/L [14]. The
findings reported herein suggest that AGE-modified pro-of AGE-b2m to prevent monocyte apoptosis was signifi-
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Table 2. Membrane antigens expression on monocytes in AGE-b2m apy for more than five years, the prevalence of radiolu-
containing cultures
cent cysts in the carpal bones, and carpal tunnel syn-
MFI (indicated mAb/isotype control) drome, were equivalent [38]. Because these are only
Treatment HLA-DR CD11b CD11c FSC (size) surrogates for b2m deposition and DRA, and other con-
ditions can result in similar radiographic and clinicalDay 0 3.3 2.8 2.2 240.0
Day 4 findings, additional study is needed to clarify the relation-
10% seruma 5.7 3.6 4.9 405.0 ship between diabetes mellitus and the rate of progres-
AGE-b2ma 4.2 3.2 3.4 310.0 sion of DRA.
Monocytes were cultured for 2 hrs (day 0) and four days with RPMI 1640
The Fas–FasL interaction has been found to play ancontaining 10% autologuous serum or with serum-free medium containing 100
mg/mL of AGE-b2m. The results are the average of two experiments. Abbrevia- important role in the induction of spontaneous apoptosis
tions are: MFI, mean fluorescence intensity; FSC, forward light scatter.
of human monocytes. Blocking this interaction by a Fas-a Cells were more than 95% viable in cultures containing 10% autologous
serum and more than 68% viable in cultures containing AGE-b2m when analyzed. immunoglobulin fusion protein or an anti-FasL antibody
Only viable cells were analyzed for fluorescence.
greatly but not completely reduces the onset of apoptosis
[28]. In the AGE-b2m culture system, treatment of mono-
cytes with AGE-b2m at concentrations that protect the
cells from apoptosis did not markedly alter the expres-teins such as AGE-b2m have multiple effects mediated
through RAGE. Another example is offered by the ob- sion of either Fas or FasL. These findings indicate that
the protective effects on monocytes may occur at a siteservation that AGE-b2m–induced chemotaxis by human
mononuclear phagocytes is abrogated by anti-RAGE downstream of the receptor–ligand interaction, such as
through direct caspase activation [39]. Alternatively, Fas-IgG [14].
Advanced glycation end products are heterogeneous FasL–independent mechanism(s) may be induced; two
possibilities exist. AGE-b2m may have direct effects onstructures containing a variety of specific epitopes. Clari-
fication of the chemical nature of the experimental AGE the monocytes by inducing intracellular signals that delay
apoptosis or might indirectly enhance monocyte survivalresponsible for the effect on apoptosis is indeed of partic-
ular interest. Although pentosidine and CML are well- via induction of cytokines that act in an autocrine fash-
ion. Interestingly, it has been found that the productioncharacterized surrogate markers of AGE [18, 19] and
were identified in our AGE-b2m sample, neither of these of TNF-a and IL-1b, cytokines that down-regulate mono-
cyte apoptosis [10], is significantly increased in mono-structures, either artificially protein bound or in free
form, appears to protect monocytes from apoptosis. It cytes/macrophages stimulated by AGE-b2m [15]. Cas-
pace-dependent and -independent pathways by whichremains unknown whether protein bound forms of pen-
tosidine or CML, naturally present in vivo, have such AGE-modified proteins, such as b2m, rescues monocytes
from apoptosis are currently under investigation.biological effects, due to the difficulty in purifying pro-
tein bound forms of pentosidine or CML to homogene- Human peripheral monocytes differentiate into mac-
rophage-like cells when cultured with human serum fority. Another as yet unidentified AGE structure might be
responsible for the activity. more than three days [24]. In our culture system, 60%
of monocytes incubated with AGE-b2m were viable afterBecause of increased production, AGE and their pre-
cursors accumulate with diabetes mellitus and aging. three days of culture and became resistant to apoptosis,
a characteristic of in vitro–derived macrophages [30].Therefore, patients with diabetes and hyperglycemia
have higher blood concentrations of AGE than healthy Cells cultured with AGE-b2m exhibited an increase in
size and similar ultrastructural changes as monocyteseuglycemic individuals [36]. We are unaware of informa-
tion about differences in blood levels of AGE-b2m be- cultured with 10% autologous serum. Similar phenotypic
alterations, observed when adherent culture of mono-tween diabetics and nondiabetics with end-stage renal
disease (ESRD), but there is poor correlation between cytes are cultured in medium containing human serum,
may represent events occurring in vivo as monocytesserum levels of b2m and DRA [1]. If AGE are involved
in the pathogenesis of both diabetic complications and migrate out of the blood vessels and differentiate into
tissue macrophages in the absence of a specific modifyingDRA, diabetic patients with ESRD might be expected
to manifest signs and symptoms of DRA earlier than stimulus [24, 26]. The activity of the lysosomal enzymes
increased with time in cells cultured with AGE-b2m.nondiabetic patients with renal failure. However, the
five-year survival of diabetic patients with ESRD is ap- Previous studies have demonstrated that membrane sur-
face antigens are expressed at a lower amount on mono-proximately one half that of nondiabetic patients [37].
Hence, ESRD patients with diabetes may not survive cytes than on macrophages due to their smaller size and
surface area. Some antigens such as CD11c are thereforesufficiently long to clinically manifest DRA, that is, prev-
alence skewed by survival bias. In a cross sectional, case directly related to cell size, whereas others like HLA-DR
can be modulated by different biologic factors [24, 40].controlled study of ESRD patients with and without
diabetes mellitus, and receiving renal replacement ther- The three antigens investigated, HLA-DR, CD11b, and
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Table 3. TNF-a, IL-1b, and PGE2 production in monocytes cultured with serum or AGE-b2m
Day 0a Day 4a Day 6a
Treatment TNF-a IL-1b PGE2 TNF-a IL-1b PGE2 TNF-a IL-1b PGE2
Cultured with serum
Medium alone 7.961.0 2.060.4 107.366.5 3.260.5 1.160.2 79.864.5 2.960.8 0.860.2 75.564.9
LPS 1 lg/mL 203.3613.3 57.267.7 514.9648.5 193.0612.4 4.860.8 495.3669.1 185.1623.7 3.060.7 480.0629.8
AGE-b2m 100 lg/mL 24.563.4 14.462.3 118.2610.8 23.864.1 4.060.8 126.2612.8 21.163.2 3.260.7 128.8614.2
Cultured with AGE-b2m
Medium alone 7.861.3 2.160.5 109.968.1 26.261.1 4.260.5 221.6628.9 28.461.8 4.160.5 228.8636.9
LPS 1 lg/mL 207.2626.3 56.765.7 524.6651.2 285.3622.8 5.460.4 673.7642.5 294.4631.2 5.160.4 679.5675.9
AGE-b2m 100 lg/mL 25.661.5 13.762.5 124.0611.2 27.363.5 4.360.3 218.7618.6 29.264.1 4.260.4 232.6626.8
Monocytes were cultured with RPMI 1640 containing 10% autologous serum or serum-free medium containing 100 mg/mL of AGE-b2m for indicated period. The
cells were washed and incubated in fresh medium with or without LPS for 18 hours, or cultured in medium with or without of AGE-b2m for 24 hours. TNF-a, IL-1b,
and PGE2 levels in the supernatants were quantitated. The data are expressed as mean 6 SD of 3 cultures. ANOVA, P , 0.0001; duration of incubation, P 5 0.02;
culture condition, P , 0.0001; stimulation, P , 0.0001; duration of incubation 3 culture condition interaction, P , 0.0001; culture condition 3 stimulation interaction,
P 5 0.007.
a TNF-a, IL-1b, and PGE2 levels were expressed as pg/104 viable cells
CD11c, are expressed on freshly isolated monocytes. Their to the development and expansion of bone cysts at the
site of b2m amyloid deposits.expression was higher on cells cultured for four days with
In summary, AGE-b2m, a major component of amy-serum or AGE-b2m. These findings further support that
loid in DRA, delays spontaneous monocytes apoptosisAGE-b2m was capable of inducing phenotypic changes
in vitro via a pathway mediated by RAGE. Monocyterepresentative of monocyte maturation.
survival in an AGE-b2m–containing microenviroment isAlthough exhibiting phenotypic characteristics of mac-
associated with their alteration into macrophage-likerophages, monocytes maintained with AGE-b2m showed
cells that generate more reactive oxygen species anddifferent functional behavior than macrophages cultured
elaborate greater quantities of proinflammatory cyto-with serum. The ability of cultured monocytes to produce
kines and PGE2. Future in vitro studies will more fullythe reactive oxygen species, O22 and H2O2, decreases as
characterize if all the effects described herein on mono-the cells mature into macrophages in serum-containing
cyte are due to AGE modification of the protein andmedium [32]. In contrast, when monocytes were cultured
not a specific property of AGE-b2m, as suggested. If thiswith AGE-b2m, this activity was maintained. Constitutive
model is applicable in vivo, the effect of AGE-b2m onsynthesis of TNF-a, IL-1b and PGE2 also decreased as
monocyte survival and differentiation may represent anmonocytes were cultured with autologous serum. In con-
important mechanism contributing to the accumulationtrast, the constitutive production of these cytokines and
of monocytes/macrophages and the inflammatory pro-PGE2 increased in monocytes maintained by AGE-b2m. cess in DRA.This finding corresponds to reports that AGE-b2m stimu-
lates mononuclear cells to produce TNF-a, IL-1b, and
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